CY1121697T1 - Σκευασμα rna για ανοσοθεραπεια - Google Patents

Σκευασμα rna για ανοσοθεραπεια

Info

Publication number
CY1121697T1
CY1121697T1 CY20191100389T CY191100389T CY1121697T1 CY 1121697 T1 CY1121697 T1 CY 1121697T1 CY 20191100389 T CY20191100389 T CY 20191100389T CY 191100389 T CY191100389 T CY 191100389T CY 1121697 T1 CY1121697 T1 CY 1121697T1
Authority
CY
Cyprus
Prior art keywords
immunotherapy
systemic administration
present
rna preparation
following systemic
Prior art date
Application number
CY20191100389T
Other languages
English (en)
Inventor
Ugur Sahin
Heinrich Haas
Sebastian Kreiter
Mustafa DIKEN
Daniel Fritz
Martin MENG
Lena Mareen KRANZ
Kerstin REUTER
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/001319 external-priority patent/WO2013143555A1/en
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of CY1121697T1 publication Critical patent/CY1121697T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Abstract

Η παρούσα εφεύρεση βρίσκεται στο πεδίο της ανοσοθεραπείας, και συγκεκριμένα της ανοσοθεραπείας όγκου. Η παρούσα εφεύρεση αναφέρεται στην παροχή φαρμακευτικών σκευασμάτων για την παροχή RNA με υψηλή εκλεκτικότητα σε κύτταρα που παρουσιάζουν αντιγόνο, όπως είναι τα δενδριτικά κύτταρα (DCs) στην σπλήνα μετά από συστηματική χορήγηση. Συγκεκριμένα, τα σκευάσματα που περιγράφονται στο παρόν επιτρέπουν την επαγωγή ανοσοαπόκρισης μετά από συστηματική χορήγηση RNA που κωδικοποιεί αντιγόνο.
CY20191100389T 2012-03-26 2019-04-09 Σκευασμα rna για ανοσοθεραπεια CY1121697T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2012/001319 WO2013143555A1 (en) 2012-03-26 2012-03-26 Rna formulation for immunotherapy
PCT/EP2013/000902 WO2013143683A1 (en) 2012-03-26 2013-03-25 Rna formulation for immunotherapy
EP13713356.7A EP2830593B1 (en) 2012-03-26 2013-03-25 Rna formulation for immunotherapy

Publications (1)

Publication Number Publication Date
CY1121697T1 true CY1121697T1 (el) 2020-07-31

Family

ID=52114006

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191100389T CY1121697T1 (el) 2012-03-26 2019-04-09 Σκευασμα rna για ανοσοθεραπεια
CY20201100940T CY1123453T1 (el) 2012-03-26 2020-10-07 Σκευασμα rna για ανοσοθεραπεια

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100940T CY1123453T1 (el) 2012-03-26 2020-10-07 Σκευασμα rna για ανοσοθεραπεια

Country Status (8)

Country Link
EP (3) EP2830593B1 (el)
CY (2) CY1121697T1 (el)
DK (1) DK3427723T3 (el)
HR (1) HRP20190607T1 (el)
ME (1) ME03367B (el)
PL (2) PL2830593T3 (el)
RS (1) RS58794B1 (el)
SI (1) SI2830593T1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CN114344486A (zh) * 2017-10-20 2022-04-15 生物技术公司 适用于治疗的脂质体rna制剂的制备和储存
WO2020200472A1 (en) * 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy
CN113225313A (zh) * 2021-03-26 2021-08-06 大唐三门峡发电有限责任公司 一种用于dcs系统的信息安全防护系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
DE102008061522A1 (de) * 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
US20110300205A1 (en) * 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
US20130171241A1 (en) * 2010-07-06 2013-07-04 Novartis Ag Liposomes with lipids having an advantageous pka-value for rna delivery
WO2013113325A1 (en) * 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation

Also Published As

Publication number Publication date
EP3777840A1 (en) 2021-02-17
EP2830593B1 (en) 2019-02-27
PL2830593T3 (pl) 2019-08-30
EP3427723A1 (en) 2019-01-16
SI2830593T1 (sl) 2019-07-31
HRP20190607T1 (hr) 2019-07-12
EP2830593A1 (en) 2015-02-04
CY1123453T1 (el) 2022-03-24
RS58794B1 (sr) 2019-07-31
DK3427723T3 (da) 2020-10-12
PL3427723T3 (pl) 2021-01-11
EP3427723B1 (en) 2020-08-05
ME03367B (me) 2019-10-20

Similar Documents

Publication Publication Date Title
AU2017279565B2 (en) RNA formulation for immunotherapy
CY1121697T1 (el) Σκευασμα rna για ανοσοθεραπεια
CY1121232T1 (el) Τριαλκυλο κατιονικα λιπιδια και μεθοδοι χρησης αυτων
EA201290876A1 (ru) Композиции индуцированных дендритных клеток и их использование
CY1121691T1 (el) Εξατομικευμενη ανοσοθεραπεια εναντι ογκων των νευρωνων και του εγκεφαλου
CL2017001819A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer
PE20142406A1 (es) Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
CY1122453T1 (el) Νεα ανοσοθεραπεια εναντι διαφορων ογκων, οπως καρκινος του πνευμονα, οπου συμπεριλαμβανεται nsclc
MX2022003698A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
CY1116302T1 (el) Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
CR20160531A (es) Inmunoterapia novedosa contra varios tumores de la sangre, como la leucemia mielógena aguda (lma)
EP3708185A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
EA201891460A1 (ru) Композиция дендритных клеток
EA201790239A1 (ru) Молекула-носитель для антигенов
BR112014011560A2 (pt) complexos imunogênicos de carbômeros polianiônicos e polipeptídeos env, e métodos de fabricação e uso dos mesmos
MX2015017959A (es) Composiciones y metodos para inmunoterapia.
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
WO2015086354A3 (en) Novel promiscuous hpv16-derived t helper epitopes for immunotherapy
WO2014184683A3 (en) Compositions and methods for targeting antigen-presenting cells
TR201900492T4 (tr) Montanide ile bir triepitop peptidinin emülsifiye edilmesine yönelik yöntem ve bunun gerçekleştirilmesine yönelik kitler.
BR112016020373A8 (pt) composição, métodos para produção de uma célula dendrítica incubada, para preparação de uma composição e para produzir uma mistura de células, e, uso de uma composição